Sign In
Buy INVA
$21.70
+0.350 (+1.64%)
At Close: Jun 03, 2026
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
05:08pm, Wednesday, 12'th Mar 2025
Proceeds to be used to continue to advance development of Armata's phage product candidates LOS ANGELES , March 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" o
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
07:00am, Wednesday, 05'th Mar 2025
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and inf
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
04:04pm, Wednesday, 26'th Feb 2025
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and inf
Innoviva: Underappreciated Strength In Hospital Therapeutics
01:11am, Sunday, 23'rd Feb 2025
Innoviva's strong balance sheet and stable royalty income from GlaxoSmithKline provide a solid foundation for its shift to specialty therapeutics, presenting an asymmetric risk-reward profile. The com
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
07:00am, Thursday, 06'th Feb 2025
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and inf
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
07:00am, Tuesday, 26'th Nov 2024
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and inf
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a biotechnology company focused on delivering innovative therapies in critical care and infectious diseases, announced today the
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
01:30pm, Tuesday, 09'th Jul 2024
Everything is expensive these days including stocks. Amid a raging bull market, it is tough to find affordable stocks to buy.
3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge
08:00am, Thursday, 27'th Jun 2024
Finding high-growth stock opportunities is crucial to constructing a stable and prosperous portfolio. Three outstanding businesses set up for remarkable development in 2024 are highlighted here.
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
01:44pm, Tuesday, 18'th Jun 2024
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's unique business model centered around royalties and healthcare assets.
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
07:00am, Monday, 03'rd Jun 2024
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and inf
3 Under-$20 Stocks That Could Make You a Fortune
07:30am, Friday, 31'st May 2024
Purchasing stocks for less than $20 might be a wise choice for investors looking to make large gains without making big initial commitments. These three under-$20 stocks show promise.
SHANGHAI & CAMBRIDGE, Mass. & WALTHAM, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Innoviva Specialty Therapeutics today announced that China's National Medical Products Adm
Innoviva to Participate in the BofA Securities Health Care Conference
07:00am, Wednesday, 08'th May 2024
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and inf
